Receive our newsletter – data, insights and analysis delivered to you
July 28, 2009

Promising Heart Drug Multaq Now Available in US

Sanofi-Aventis has announced that Multaq (dronedarone) is now available in the US for patients with atrial fibrillation (AF) or atrial flutter (AFL). Multaq is an anti-arrhythmic drug indicated to reduce the risk of cardiovascular hospitalisation in patients with paroxysmal or persisten

By cms admin

Sanofi-Aventis has announced that Multaq (dronedarone) is now available in the US for patients with atrial fibrillation (AF) or atrial flutter (AFL).

Multaq is an anti-arrhythmic drug indicated to reduce the risk of cardiovascular hospitalisation in patients with paroxysmal or persistent AF or AFL.

The announcement follows approval granted by the US Food and Drug Administration (FDA) on 1 July 2009.

Pennsylvania State University College of Medicine Division of Cardiology chief Gerald V Naccarelli said that the drug is a welcome new option.

“Multaq may help patients with AF or AFL stay out of the hospital, an important factor in treatment that is often not addressed,” Naccarelli said.

Approval was granted based on the landmark ATHENA trial, in which the efficacy and safety of Multaq was evaluated in patients with AF/AFL or a recent history of these conditions.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The trial showed that Multaq 400mg BID, in addition to standard therapy, reduced the combined endpoint of cardiovascular hospitalisation or death from any cause by 24% when compared to placebo.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU